Health Bureau renews drug regulation agreement

The government will also establish a clinical trial facility in Hetao this year.

The Health Bureau and the National Medical Products Administration (NMPA) renewed the cooperation agreements on the Regulation of Drugs and the Construction, Research, & Management of Chinese Medicines Herbarium.

This follows the government’s “primary evaluation” approach to enhance the approval and registration of drugs and the establishment of an internationally recognised regulatory authority for drugs and medical devices announced at the 2023 Policy Address.

The government will also establish the Greater Bay Area International Clinical Trial Institute (GBAICT) in Hetao this year to provide a one-stop clinical trial support services in Hong Kong to transform the city into a leading clinical trial hub in Asia.

In addition, the Government Chinese Medicines Testing Institute launched the Digital Herbarium for Chinese Medicines website with information on over 220 types of commonly used Chinese materia medica.